Incannex Healthcare (IXHL) Competitors $1.05 -0.58 (-35.58%) Closing price 07/25/2025 04:00 PM EasternExtended Trading$1.10 +0.05 (+5.24%) As of 07/25/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock IXHL vs. DARE, NRSN, MIRA, NNVC, FBLG, TPST, ALXO, QTTB, CVKD, and TENXShould you be buying Incannex Healthcare stock or one of its competitors? The main competitors of Incannex Healthcare include Dare Bioscience (DARE), NeuroSense Therapeutics (NRSN), MIRA Pharmaceuticals (MIRA), NanoViricides (NNVC), FibroBiologics (FBLG), Tempest Therapeutics (TPST), ALX Oncology (ALXO), Q32 Bio (QTTB), Cadrenal Therapeutics (CVKD), and Tenax Therapeutics (TENX). These companies are all part of the "pharmaceutical products" industry. Incannex Healthcare vs. Its Competitors Dare Bioscience NeuroSense Therapeutics MIRA Pharmaceuticals NanoViricides FibroBiologics Tempest Therapeutics ALX Oncology Q32 Bio Cadrenal Therapeutics Tenax Therapeutics Dare Bioscience (NASDAQ:DARE) and Incannex Healthcare (NASDAQ:IXHL) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, media sentiment, valuation, profitability, analyst recommendations, earnings and dividends. Do insiders & institutionals have more ownership in DARE or IXHL? 6.7% of Dare Bioscience shares are owned by institutional investors. Comparatively, 0.4% of Incannex Healthcare shares are owned by institutional investors. 4.0% of Dare Bioscience shares are owned by company insiders. Comparatively, 15.5% of Incannex Healthcare shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Do analysts prefer DARE or IXHL? Dare Bioscience presently has a consensus price target of $12.00, suggesting a potential upside of 366.93%. Given Dare Bioscience's stronger consensus rating and higher possible upside, equities analysts plainly believe Dare Bioscience is more favorable than Incannex Healthcare.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dare Bioscience 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50Incannex Healthcare 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has stronger earnings & valuation, DARE or IXHL? Dare Bioscience is trading at a lower price-to-earnings ratio than Incannex Healthcare, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDare Bioscience$10K2,274.45-$4.05M-$0.17-15.12Incannex Healthcare$10K3,090.15-$18.46M-$1.21-0.87 Which has more volatility & risk, DARE or IXHL? Dare Bioscience has a beta of 1.14, suggesting that its share price is 14% more volatile than the S&P 500. Comparatively, Incannex Healthcare has a beta of 7.47, suggesting that its share price is 647% more volatile than the S&P 500. Is DARE or IXHL more profitable? Dare Bioscience's return on equity of 0.00% beat Incannex Healthcare's return on equity.Company Net Margins Return on Equity Return on Assets Dare BioscienceN/A N/A -8.14% Incannex Healthcare N/A -342.92%-148.64% Does the media refer more to DARE or IXHL? In the previous week, Incannex Healthcare had 4 more articles in the media than Dare Bioscience. MarketBeat recorded 7 mentions for Incannex Healthcare and 3 mentions for Dare Bioscience. Dare Bioscience's average media sentiment score of 0.63 beat Incannex Healthcare's score of 0.37 indicating that Dare Bioscience is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dare Bioscience 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Incannex Healthcare 0 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryDare Bioscience beats Incannex Healthcare on 9 of the 14 factors compared between the two stocks. Get Incannex Healthcare News Delivered to You Automatically Sign up to receive the latest news and ratings for IXHL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IXHL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IXHL vs. The Competition Export to ExcelMetricIncannex HealthcareMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$47.98M$2.49B$5.69B$9.50BDividend YieldN/A1.65%4.58%4.01%P/E Ratio-0.879.0528.1020.05Price / Sales3,090.15612.51432.4490.07Price / CashN/A165.2136.2258.56Price / Book5.835.168.665.87Net Income-$18.46M$30.99M$3.25B$258.55M7 Day Performance72.13%7.74%4.23%3.74%1 Month Performance402.15%16.27%10.52%11.75%1 Year Performance-51.54%-1.88%34.41%18.03% Incannex Healthcare Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IXHLIncannex Healthcare0.7438 of 5 stars$1.05-35.6%N/A-51.4%$47.98M$10K-0.873News CoverageGap DownDAREDare Bioscience1.7944 of 5 stars$3.09+22.6%$12.00+288.3%-28.6%$27.35M$10K-18.1830High Trading VolumeNRSNNeuroSense Therapeutics2.711 of 5 stars$2.00-3.4%$14.00+600.0%+150.6%$27.33MN/A-3.7010MIRAMIRA Pharmaceuticals2.5957 of 5 stars$1.54+20.3%$14.00+809.1%-43.1%$26.06MN/A-3.022High Trading VolumeNNVCNanoViricides0.3562 of 5 stars$1.60+14.7%N/A-24.0%$25.72MN/A-2.2220High Trading VolumeFBLGFibroBiologics3.8169 of 5 stars$0.64+1.7%$13.00+1,931.3%-85.8%$25.40MN/A-3.0510Positive NewsGap UpTPSTTempest Therapeutics2.3334 of 5 stars$6.90-0.7%$30.00+334.8%-65.3%$25.39MN/A-0.3820Positive NewsALXOALX Oncology3.8518 of 5 stars$0.47-2.8%$3.30+603.9%-91.4%$25.03MN/A-0.1940Positive NewsQTTBQ32 Bio2.4823 of 5 stars$2.03-23.7%$12.17+499.3%-94.2%$24.77M$1.16M-0.4139News CoverageHigh Trading VolumeCVKDCadrenal Therapeutics3.1047 of 5 stars$12.50-3.3%$32.00+156.0%N/A$24.59MN/A-1.354Positive NewsTENXTenax Therapeutics1.8082 of 5 stars$5.90+1.7%$17.50+196.6%+82.2%$24.47MN/A-2.389Positive News Related Companies and Tools Related Companies Dare Bioscience Alternatives NeuroSense Therapeutics Alternatives MIRA Pharmaceuticals Alternatives NanoViricides Alternatives FibroBiologics Alternatives Tempest Therapeutics Alternatives ALX Oncology Alternatives Q32 Bio Alternatives Cadrenal Therapeutics Alternatives Tenax Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IXHL) was last updated on 7/26/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump's 2025 Economic Revolution Is Here Are Your Retirement Savings Ready?Time is short. Trump's reforms may be coming fast—and the financial system roller coaster may be a ride that y...Create New Advertiser | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…GoldCo Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Incannex Healthcare Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Incannex Healthcare With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.